INTRODUCTION
============

Four different types of human T-lymphotropic viruses (HTLV) have been described in humans. Human T-lymphotropic virus type 1 (HTLV-1) was the first retrovirus infecting humans to be discovered in 1980[@B01], and 15-20 million people are estimated to be infected worldwide[@B02] ^-^ [@B04]. Endemic foci of infection have been reported in Japan, Melanesia, Iran, Central and West Africa, the Caribbean, and South America[@B05]. In Europe, North America, and Australia, HTLV-1 infection is rare and mainly found in immigrants coming from endemic areas, and their sexual partners and descendants[@B06] ^,^ [@B07]. Although most HTLV-1-infected people remain asymptomatic throughout their lives, approximately 3% develop adult T cell leukemia/lymphoma (ATLL) and another 3% develop HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)[@B08].

HTLV-2 was discovered in 1982, and it is estimated that 3-5 million people are chronically infected. It is mostly prevalent among intravenous drug users in North America and Western Europe, although endemic infections can be found in some Amerindian and African pygmy tribes. In contrast to HTLV-1, the pathogenicity of HTLV-2 is very low and has only occasionally been linked to subacute neurological syndromes, including HTLV-2-like paraparesis, neuropathies, and bladder disturbances[@B07] ^,^ [@B09] ^-^ [@B14].

In 2005, HTLV type 3 (HTLV-3) was discovered in two asymptomatic inhabitants from South Cameroon. More recently, two other cases of HTLV-3 infection in people living in Cameroon were reported, suggesting that this virus is not extremely rare in the human population living in Central Africa[@B15]. Finally, only one strain of HTLV-4 has been identified in a person who also lived in Cameroon[@B16].

The basic premise for bibliometrics is that scientific knowledge is mainly transmitted through publications that report research results, which in turn allowed us to analyze the development of the scientific field in question. By carrying out a quantitative analysis of scientific publications in a given field, we can draw conclusions on how that research field evolves and develops[@B17] ^,^ [@B18].

There have been publications analyzing research production for other viral infections, such as John Cunningham virus[@B19], Nipah virus[@B20], avian influenza virus[@B21], H1N1 influenza virus[@B22], and papillomavirus[@B23]among others. As for HTLV, one short quantitative study analyzing research output for the period between 2001 and 2010 using the PubMed was reported at an international conference as a poster presentation[@B24]. Another study analyzed scientific production in the field of the motor neuron diseases, Konzo and neurolathyrism, in comparison with HTLV-1/ HAM/TSP over 21 years (from 1990 to 2010) through the Web of Science database[@B25]. As HTLV-1 can be considered a neglected public health problem[@B26], and ATLL and HAM/TSP can be considered neglected diseases, this would provide more focus on this condition[@B27].

The aim of this study was to investigate HTLV research output using PubMed database, covering a period of 24 years (1989-2012): by journal of publication, country, forms of disease, author production, and collaboration patterns.

METHODS
=======

The Medline database, accessible and free of charge through the PubMed platform, was selected as the most suitable database to search for HTLV publications, due to its volume and coverage. PubMed was accessed online in December 28, 2013. For retrieving documents, a search was made comprising the MeSH terms or descriptors: \"Human T-lymphotropic virus 1\", \"Human T-lymphotropic virus 2\", \"Human T-lymphotropic virus 3\", \"HTLV-II Antigens\", \"HTLV-II Antibodies\", \"HTLV-I Antigens\", \"HTLV-I Antibodies\", \"HTLV-II Infections\", and \"HTLV-I Infections\". The study period was from January 1, 1989 to December 31, 2012. We decided to begin in 1989 because a different HTLV MeSH term was introduced in 1989. No language or document type restriction was considered in the search, so that publication patterns for all publications on HTLV could be analyzed.

The document type used in our study refers to the type of article according to PubMed (journal article, letter, editorial, review, etc.). Financial support was analyzed.

Productivity by country was analyzed considering the number of papers and percentage of world production. It should be noted that institutional affiliation is only included for the first participating author in the PubMed database in*Journal articles* and *Reviews*. Indicators for each country\'s productivity between 1989 and 2012 were standardized with respect to the median population, gross domestic product (GDP), GDP per capita and health expenditure (HE) per capita. To calculate the publications per million inhabitants (population index), per 10 billion US dollars of GDP (GDP index), per 1,000 US dollars of GDP per capita (GDP per capita index), and per 100 US dollars of HE per capita (HE per capita index), data were obtained from *World Development Indicators* from the World Bank online databases[@B28].

Based on geographical, scientific, and economic criteria, the world was divided into six regions according to the composition of macrogeographical (continental) regions, geographical subregions, and selected economic regions and other unidata groupings from the United Nations Statistics Division[@B29]. The forms of diseases were classified as HTLV-I, HTLV-II, ATLL and HAM/TSP according to the MeSH term.

A number of widely used bibliometric indicators were calculated to characterize the scientific collaboration on HTLV, the percentage of documents signed in collaboration and the average number of coauthors per paper. A coauthorship network analysis was carried out. Coauthorship networks are made up of nodes (authors) and ties between them (coauthorship links). We identified the nodes that function as \"cutpoints\" or intermediates facilitating connectivity between parts of the network that would otherwise be unconnected, and we also made different statistical calculations relating to centrality. These indicators are commonly used in Social Network Analysis (SNA) and include the concept of \"degree\" and \"betweenness,\" used to characterize the role played by different investigators in the network and to determine the most important and influential authors in it. BibExcel software was used for the treatment and standardization of the bibliographical information, and the Pajek program was used to analyze and generate a visualization of the coauthorship network.

The Committee for Security of Information and Research at the *Hospital General Universitario de Alicante* provided ethical approval for this study.

RESULTS
=======

In the PubMed database, a total of 7,564 references were retrieved during the entire study period. The number of documents decreased during the overall study period; the global figures per six-year period are as follows: 2,717 (35.9%) publications from 1989 to 1994; 2,236 (29.6%) from 1995 to 2000; 1,387 (18.3%) from 2001 to 2006; and 1,224 from 2007 to 2012 (16.2%) ([Fig. 1](#f01){ref-type="fig"}).

Fig. 1- Number of HTLV research publications in PubMed between 1989 and 2012, per 6-year period.

**Language and type of documents:** The primary language was English (89.1%), followed by Japanese (5.1%), Spanish (2.0%), and French (1.7%). The main type of document was \"Original paper contribution\" (77.8%), followed by \"Review\" (11.7%), and \"Letter\" (8.5%). Almost 53% of documents were original researches, only 0.8% were clinical trials, and 0.04% were meta-analysis studies.

**Journal of publication:** The 7,564 retrieved articles were published in 1,074 different scientific journals. Ten journals accounted for 25.8% of HTLV journal literature. About one half of the articles was concentrated in 44 journals, while the remaining half was spread over 1,030 journals. Moreover, 498 journals published only one paper on HTLV. The journals area mainly include the fields of virology (n = 10), hematology (n = 9), immunology (n = 8), oncology (n = 7), clinical neurology (n = 5), and infectious diseases (n = 5) among others.

**Topics and MeSH:** The MeSH \"Human T-lymphotropic virus 1\", \"HTLV infection\", \"HTLV-I Antibodies\", \"HTLV-II Infections\", \"Human T-lymphotropic virus 2\", \"HTLV-II Antibodies\", \"HTLV-I Antigens\", and \"HTLV-II Antigens\" were reported in 62.8%, 40.7%, 14.8%, 10.4%, 10.1%, 3.8%, 2.6%, and 0.4% of articles respectively. About 88.5% of documents (n = 6,697) were about HTLV-I, 16.6% of documents (n = 1,259) were about HTLV-II, and 12.3% of documents referred to both HTLV-I and HTLV-II.

The main MeSH infections associated with HTLV were: \"Paraparesis, Tropical Spastic\" (18.8%), \"Leukemia-Lymphoma, Adult T-Cell\" (11.9%), \"Leukemia, T-Cell\" (4.8%), \"Skin Neoplasms\" (1.4%), and \"Uveitis\" (1.2%). The main MeSH associated with virology of HTLV were: \"Molecular Sequence Data\" (15.9%), \"Gene Products, tax\" (13.8%), \"DNA viral\" (12.2%), \"Cell Line\" (12.1%), and \"Base sequence\" (11.9%). The MeSH \"HIV 1\", \"HIV Infections\", \"HIV-2\", \"HIV\", \"HIV antibodies\", and \"HIV seropositivity\" were reported in 7.5%, 5.8%, 1.8%, 1.8%, 1.7%, and 1.5% of documents.

**Countries of publication:** Authors\' affiliation was available in 6,590 of the 7,564 documents recovered (87.1%). [Table 1](#t01){ref-type="table"} ranks countries in crude numbers of retrieved articles and numbers corrected by population index, GDP index, GNI per capita index, and HE per capita index. The first and second countries were Japan and USA, respectively, accounting for more than 61% of publications, followed by France, Brazil, and United Kingdom. When normalized by population, the order of prominence was Dominica, Japan, Jamaica, Curacao, and Grenada. Once normalized by GDP, we found that among low and middle-income countries, Guinea-Bissau, Gambia, Dominica, Jamaica, and Saint Vincent and the Grenadines were the most productive. If we calculate the ratio of the number of HTLV publications to GDP per capita, Brazil, Japan, USA, China, and India were the most productive. When normalized by HE per capita, the leading order was Brazil, Japan, India, China, and Democratic Republic of the Congo.

Table 1Top 20 countries and world regions ranked according to total number of publications, publications per inhabitant, per gross domestic product (GDP), GDP per capita and health expenditure (HE) per capita in 6,590 human T-lymphotrophic virus manuscripts with institutional address of the first author.**CountryN. of docs. (%)CountryPopulation index\*CountryGDP index\*\*CountryGDP per capita index\*\*\*CountryHE per capita index\*\*\*\***1.Japan2,116 (32.1)1.Dominica28.271.Guinea-Bissau175.811.Brazil78.571.Brazil90.282.USA1,952 (29.6)2.Japan16.742.Gambia82.632.Japan59.582.Japan74.253.France524 (8.0)3.Jamaica14.783.Dominica63.393.USA52.833.India57.654.Brazil415 (6.3)4.Curaçao14.444.Jamaica42.394.China26.094.China48.995.UK248 (3.8)5.Grenada9.865.St.Vincent ^\#\#^41.755.India25.465.Congo^\#\#\#^43.846.Italy194 (2.9)6.St.Vincent^\#\#^9.236.Grenada23.116.Guinea-Bissau24.156.Guinea-Bissau34.147.Germany106 (1.6)7.Gabon8.787.Gabon20.067.Congo^\#\#\#^23.017.Mozambique33.978.Canada85 (1.3)8.France8.518.Lebanon13.768.Mozambique22.038.USA32.589.Spain77 (1.2)9.Israel7.469.Mozambique13.609.France18.039.South Korea28.1410.Belgium60 (0.9)10.Lebanon7.4510.Central A. R.^\#\#\#\#^10.8910.Nigeria14.2210.Gambia27.8011.Chile54 (0.8)11.USA6.9211.Senegal7.3311.Peru13.7211.Peru26.2012.Israel47 (0.7)12.Guinea-Bissau6.1512.South Korea6.5412.Jamaica11.0612.Ethiopia24.5813.China45 (0.7)13.Belgium5.7813.Trinidad^\#^6.2813.Gambia10.4513.Jamaica19.9014.Australia42 (0.6)14.Denmark5.6114.Peru5.1314.Ethiopia9.8814.Tanzania17.9515.Argentina41 (0.6)15.Trinidad^\#^4.7015.Togo5.0615.Iran9.3815.Nigeria17.8016.Peru39 (0.6)16.Gambia4.6716.Chile5.0516.Tanzania9.3216.France15.3617.Jamaica38 (0.6)17.UK4.1717.Congo^\#\#\#^5.0417.UK8.6217.Cameroon14.2518.Sweden33 (0.5)18.Ireland3.8018.Japan4.7118.Chile8.1218.Ghana14.1119.Netherlands31 (0.5)19.Barbados3.7119.Brazil4.3319.Ghana7.8019.Bangladesh13.9720.Denmark30 (0.5)20.Sweden3.6920.Cameroon4.1120.Italy7.5920.Senegal12.76World regionN. of docs.World regionPopulation index\*World regionGDP index\*\*World regionGNI per capita index\*\*\*World regionHE per capita index\*\*\*\*1.Asia2,223 (33.7)1.North America6.501.Latin America & the Caribbean2.431.North America30.681.Asia31.692.North America2,037 (30.9)2.Europe1.952.North America1.762.Asia12.432.North America22.333.Europe1,419 (21.5)3.Oceania1.733.Sub-Saharan Africa1.693.Latin America & the Caribbean2.293.Latin America & the Caribbean6.004.Latin America & the Caribbean658 (10.0)4.Latin America & the Caribbean1.234.Asia1.174.Europe1.444.Sub-Saharan Africa2.535.North Africa125 (1.9)5.Asia0.665.Europe1.105.Sub-Saharan Africa1.385.Europe1.996.Sub-Saharan Africa86 (1.3)6.North Africa0.306.North Africa0.736.North Africa0.646.North Africa1.467.Oceania42 (0.6)7.Sub-Saharan Africa0.147.Oceania0.617.Oceania0.537.Oceania0.70Total6,590 (100)Total1.08Total1.66Total3.22Total5.21[^2]

Asia and North America were by far the most productive continents in the field of HTLV, responsible for 64.4% of all articles ([Table 1](#t01){ref-type="table"}). The ranking corrected by population ranked North America and Europe in first position, and when normalized by GDP, the order of prominence was Latin America and the Caribbean, followed by North America. Once normalized by GDP per capita, the leading order was North America and Asia, and after being normalized by HE per capita, Asia and North America were the most productive ([Table 1](#t01){ref-type="table"}).

Japan and USA were the most productive countries regarding HTLV-1. USA ranked first in HTLV-II followed by Brazil. Japan followed by USA and Brazil were the most productive in HAM/TSP. In ATLL, Japan followed by USA and France were in the lead. Asia, North America, and Europe ranked first in HTLV-I and ATLL; North America, Europe, Latin America and the Caribbean led in HTLV-II; and Asia, North America, and Latin America and the Caribbean had the highest number of publications in HAM/TSP ([Table 2](#t02){ref-type="table"}).

Table 2Top 20 countries and world regions ranked according to total number of publications by forms of human T-lymphotrophic virus (HTLV) types and diseases associated with HTLV (Tropical spastic paraparesis and adult T cell leukemia/lymphoma) in 6,590 HTLV manuscripts with institutional address of the first author.**HTLV-1HTLV-2Tropical spastic paraparesisAdult T cell leukemia/lymphoma**CountryN. of docs.%CountryN. of docs.%CountryN. of docs.%CountryN. of docs.%Japan1,85831.7USA45943.6Japan47337.7Japan41751.4USA1,73829.7Brazil11010.4USA23518.7USA19524.0France4998.5France787.4Brazil16713.3France536.5Brazil3435.9Japan656.2France927.3Brazil303.7UK2324.0Italy636.0UK655.2UK162.0Italy1622.8Spain373.5Chile322.5Germany141.7Germany1011.7Argentina302.8Italy171.4Lebanon121.5Canada741.3UK252.4Canada171.4Italy91.1Spain621.1Belgium232.2Spain161.3Canada81.0Belgium510.9Canada131.2Jamaica151.2China60.7Israel440.8Netherlands131.2Germany141.1Chile50.6Chile430.7Sweden121.1Peru121.0Iran50.6China430.7Peru100.9Colombia110.9Greece40.5Australia370.6Germany90.9Israel80.6Peru30.4Peru370.6Ireland90.9Belgium60.5Colombia30.4Argentina340.6Mexico80.8Australia60.5Argentina30.4Jamaica330.6Israel60.6Sweden60.5Netherlands30.4Netherlands310.5Norway60.6South Africa60.5Senegal30.4Denmark300.5Cuba50.5Argentina40.3Spain20.2Sweden290.5Saudi Arabia50.5China30.2Jamaica20.2HTLV-1HTLV-2Tropical spastic paraparesisAdult T cell leukemia/lymphomaWorld regionN. of docs.%World regionN. of docs.%World regionN. of docs.%World regionN. of docs.%Asia1,96033.5North America47244.8Asia48245.8Asia42640.5North America1,81230.9Europe29528.0North America25223.9North America20319.3Europe1,29922.2Latin America & the C.17516.6Latin America & the C.25123.8Europe11010.4Latin America & the C.5509.4Asia787.4Europe23021.8Latin America & the C.474.5North Africa1131.9North Africa181.7Sub-Saharan Africa212.0North Africa191.8Sub-Saharan Africa801.4Sub-Saharan Africa100.9North Africa141.3Sub-Saharan Africa70.7Oceania370.6Oceania40.4Oceania60.5Oceania00.0Total5,855100Total1,053100Total1,256100Total812100[^3]

**Authorship:** [Table 3](#t03){ref-type="table"} ranks the 20 most productive authors for each form of the disease. For global HTLV research, the main author was M. Osame, a Japanese researcher (n = 217 documents), followed by A. Gessain (n = 158), a French investigator, and Y. Tanaka (n = 150), another Japanese scientist. For HTLV-1, the main author was M. Osame (n = 146), Y. Tanaka (n = 142) and A. Gessain (n = 141). In HTLV-2, the main author was R.B. Lal (n = 64), a North American researcher, followed by E.L. Murphy (n = 58), another North American investigator and V. Soriano (n = 48), a Spanish scientist. M. Osame (n = 170) led in HAM/TSP research, while M. Matsuoka (n = 48) led in ATLL research.

Table 3Twenty most-productive authors ranked according to total number of publications by forms of human T-lymphotrophic virus (HTLV) types and diseases associated with HTLV (Tropical spastic paraparesis and adult T cell leukemia/lymphoma).**TotalHTLV-1 (n=6,697)HTLV-2 (n=1,259)Tropical spastic paraparesis (n=1,422)Adult T cell leukemia/lymphoma (n=900)**AuthorN. of docs.AuthorN. of docs.AuthorN. of docs.AuthorN. of docs.AuthorN. of docs.Osame, M217Osame, M146Lal, RB64Osame, M170Matsuoka, M48Gessain, A158Tanaka, Y142Murphy, EL58Izumo, S91Yamada, Y42Tanaka, Y150Gessain, A141Soriano, V48Jacobson, S77Mori, N39Jacobson, S112Jacobson, S96Gessain, A40Usuku, K56Tomonaga, M37Izumo, S110Lairmore, MD95Kaplan, JE39Nakamura, T51Tanaka, Y34Lairmore, MD103Yamaguchi, K95Hall, WW35Bangham, CRM45Utsunomiya, A27Yamaguchi, K99Bangham, CRM92Poiesz, BJ33Cartier, L41Kamihira, S26Bangham, CRM96Izumo, S83Green, PL30Kubota, R40Yamaguchi, K25Lal, RB93Matsuoka, M80Rudolph, DL30Araújo, AQC35Gessain, A22Blattner, WA86Blattner, WA75De Thé, G28Gessain, A33Kannagi, M22Murphy, EL85Taylor, GP74Khabbaz, RF28Saito, M32Ohshima, K22Soriano,V84Franchini, G70Vandamme, AM27Itoyama, Y31Ikeda, S21Matsuoka, M83Mori, N69Bertazzoni, U25Nagataki, S29Hermine, O21Taylor, GP80Jeang, K-T68Lairmore, MD24Kira, JI29Masuda, M21Nakamura, T76Lal, RB67Chen, IYS24Nakagawa,M28Takatsuki, K20Franchini, G71Murphy, EL67Mahieux, R23Taylor, GP27Watanabe, T19Takatsuki, K70Soriano, V67Casoli, C23Ijichi, S27Sonoda, S18Sonoda, S70Watanabe, T67Blattner, WA21Nagai, M25Bazarbachi, A17Mahieux, R69Takatsuki, K66Gutiérrez, M21Umehara, F25Waldmann, TA16Watanabe, T69Sonoda, S66Rosenblatt, JD21Eguchi, K24Maeda, Y16[^4]

**Collaboration networks:** Nearly all of the \"original paper contributions\" (96.66%, n = 5,671) were signed in collaboration, at an average number of 6.2±3.0 coauthors per paper. The evolution through time shows a steady increase in collaborative work, rising from an average of 5.6 ± 2.8 authors per work in 1989 to 7.2 ± 4.0 in 2012.

Virtually all of the authors (99.7%) established at least one collaborative link; on average, they collaborated with 11.7 other authors on different papers. Among the most productive authors (\> 9 papers), this number was considerably higher, at 71.6 ± 56.6. However, these authors only had consolidated, stable ties with a handful of colleagues; the average number of collaborators with whom they had signed eight or more papers was 2.4±3.0.

Quantifying the different author pairs, we identified 88,919 coauthorship links. Most of these collaborations were isolated, as 83.3% (n = 74,063) were limited to coauthoring one paper, whereas 9.8% (n = 8,763) of the pairs coincided twice and 6.3% (n = 5,673) of the ties were present in 3-9 papers.

Only 420 (0.5%) of the coauthorships occurred in 10 or more documents. An analysis and graphical representation of all the coauthorship links in the form of a network show that 85.1% (n = 12,952) of the authors appear interconnected, either directly or through intermediates in a larger research group or in a main component.

We applied a collaboration threshold of eight or more coauthored articles in order to identify and analyze the main research groups, with the most consolidated relationships among its members. We were able to identify 80 clusters, made up of 516 authors. One large group stands out, bringing together 174 authors and six other clusters, each of which consists of more than nine authors. The authors that participate in these clusters are specialized in the study of the same disease in the same geographical proximity; they come primarily from Japan, the USA, and a few European countries, including Belgium, France, and Spain. Calculating the centrality measures used in SNA and identifying the cutpoints it was possible to show how some authors exercise a prominent role as intermediates, bringing together a high number of investigators, or facilitating links between dispersed authors and research foci in the network. Y. Tanaka heads the ranking by betweenness (indicator of the node\'s centrality in the network), followed by C.R.M. Bangham, S. Kamihira, K. Yamaguchi, and Y. Yamada. M. Osame is the first in degree (number of ties that a vertex has to other vertices in its network), followed by S. Izumo, T. Nakamura, A. Gessain, V. Soriano, Y. Tanaka, and E.L. Murphy. [Table 4](#t04){ref-type="table"}lists the top 17 authors ranking according betweenness and degree of centrality measures as well as the number of published original articles, and [Fig. 2](#f02){ref-type="fig"} is a graphical visualization of the main research foci, with labels to identify the most prominent authors.

Table 4Top 17 authors based on centrality measures and the total number of publications.**RankAuthorBetweennessAuthorDegreeAuthorN of articles**1Tanaka, Yuetsu0.000071Osame, Mitsuhiro27Osame, Mitsuhiro1832Bangham, Charles RM0.000056Izumo, Shuji20Tanaka, Yuetsu1383Kamihira, Shimeru0.000053Nakamura, Tatsufumi18Gessain, Antoine1214Yamaguchi, Kazunari0.000050Gessain, Antoine17Izumo, Shuji1015Yamada, Yasuaki0.000047Soriano, Vicente17Jacobson, Steven966Okayama, Akihiko0.000039Tanaka, Yuetsu16Lairmore, Michael D937Osame, Mitsuhiro0.000032Murphy, Edward L15Lal, Renu B778Fujii, Masahiro0.000029Yamada, Yasuaki14Murphy, Edward L769Kannagi, Mari0.000028Kamihira, Shimeru13Yamaguchi, Kazunari7410Izumo, Shuji0.000020Bangham, Charles RM12Bangham, Charles RM7211Hisada, Michie0.000019Nagataki, S12Blattner, WA6912Utsunomiya, Atae0.000017Usuku, Koichiro11Taylor, Graham P6613Yamamoto, Naoki0.000016Yamamoto, Naoki11Nakamura, Tatsufumi6514Murphy, Edward L0.000016Yamaguchi, Kazunari10Yamamoto, Naoki6215Sonoda, Shunro0.000016Okayama, Akihiko10Okayama, Akihiko6116Uozumi, Kimiharu0.000016Eguchi, Katsumi10Brady, John N6017Hanchard, Barrie0.000013Tomonaga, Masao10Sonoda, Shunro60

Fig. 2- Main research foci in scientific publications on HTLV. Shapes: ellipse (research focus on HTLV-1-associated myelopathy/Tropical spastic paraparesis); triangle (research focus on Adult T-cell leukemia/lymphoma).

DISCUSSION
==========

Some authors have highlighted the importance of HTLV-1-associated myelopathy/tropical spastic paraparesis, the main disease associated with HTLV-1, that many consider to be neglected[@B27]. Its burden is overwhelmingly concentrated (with the exception of Japan) in poor countries; there is no adequate intervention for its prevention or treatment, and neither the pharmaceutical industry nor other private funders have invested much in research on the topic[@B26]. Moreover, few studies offer current data on the disease\'s prevalence or incidence in countries where it is endemic or on the high proportion of underdiagnosed cases and late diagnosis a consequence of its asymptomatic nature. There is also a dearth of studies investigating treatments for the diseases associated with the virus[@B03]. The formal consideration of tropical spastic paraparesis (and by extension, HTLV) as a neglected disease would be in the interest of researchers on the topic, providing as the classification has for other neglected diseases an impulse for new studies. The most prominent, current authors and research groups on HTLV could then become reference points, facilitating the integration of new investigators.

This study has shown a decrease in the number of publications on HTLV over a 24 year period (1989-2012). Most scientific production has increased over the last few years, although others[@B19] ^,^ [@B23], like leprosy, have experienced reduced trends since the turn of the century[@B34]. There are different explanations for this decrease, the first of which being the decrease in the prevalence of HTLV infection due to the control of virus transmission, especially in Japan[@B01]. Secondly, the discovery of HIV-1 infection in 1983 and the worldwide morbidity and mortality impact of AIDS has led to almost all resources being concentrated on this disease in the last two decades. In addition, most retrovirologists have focused on the HIV field and HTLV infection has been forgotten. Thirdly, since the disease associated with HTLV-2, and HAM/TSP or ATLL associated with HTLV-1 infection are poorly prevalent and do not have an effective therapy[@B03] ^,^ [@B06], there is not much research interest within the scientific community. Finally, there is no effective antiretroviral therapy in contrast to other infections like HIV, herpesvirus or hepanavirus, and pharmaceutical financial support is extremely low. Therefore, although the availability of new journals in PubMed focusing on retroviruses, like*Retrovirology* [@B24], may provide a positive feedback for HTLV research papers, there is less interest in this field than before[@B19] ^,^ [@B23].

Although most HTLV manuscripts are written in English (89.1%), following the trends for scientific diffusion in the research field[@B23], another relevant language was Japanese (5.1%). HTLV is endemic in Japan[@B03] ^-^ [@B05], which might explain the prevalence of this language with respect to others.

Original papers were the most commonly retrieved document type (approximately 77.8%), similar to other bibliometric studies on virus research[@B23]. Although controlled trials offer the best evidence for medical intervention efficacy[@B30], in this study they represented only 0.8% of the documents, which would explain the resulting absence of effective antiretroviral therapy for HTLV infection.

Japan was the leading country in publication output on HTLV. As HTLV is endemic in Japan[@B03] ^-^ [@B05], this might explain the prevalence of this country with respect to others. USA, which was the second country, has excelled in virology[@B19] ^,^ [@B22] as well as other biomedical fields[@B31]. France was the third country, with more HTLV publications than in any other biomedical field[@B31] ^-^ [@B34], probably due to a higher relevance of virology research in this country.

HTLV is also endemic in South America, especially among several native peoples[@B35] ^,^ [@B36]. Brazil was the fourth country, and led scientific production on HTLV in Latin America. Moreover, this country has increased its overall production during the study period as well as its relative contribution. This can be attributed to a greater research projection for the future and the large population living there, as well as to the number of researchers and the development of the country\'s scientific system, which has become the main scientific reference for South America[@B22] ^,^ [@B37]. Brazil also has a large stake in neglected tropical diseases, which are a priority for public health due to their high incidence (Chagas diseases or Leishmaniasis)[@B34] ^,^ [@B38]. In several bibliometric studies on other neglected diseases[@B34] ^,^ [@B38], Brazil has been a leading country in South America, and is, to be more precise, important as a South American network core. Although HTLV is endemic to central Australia among indigenous Australians, virology and clinical aspects of HTLV infection remain poorly described and there are scanty scientific publications from Australia[@B39].

In HTLV-1 and ATLL, the leading countries were Japan and USA followed by France. In HTLV-2 the leading country was USA followed by Brazil and France. HTLV-2 research was less important among Japanese scientists, which is due to the fact that HTLV-2 infects intravenous drug users (IDUs) in USA and Europe, and Amerindian tribes in Latin American countries[@B40].

In HAM/TSP, the leading country was Japan, followed by USA and Brazil. The HAM/TSP incidence density among HTLV-1-seropositive cases observed in current asymptomatic individuals in Brazil is higher than that in studies in other countries[@B41] ^,^ [@B42]. For intance, Brazilian scientists had a special relevance in research on HTLV with HAM/TSP[@B27] ^,^ [@B41].

Asia and North America were the world\'s leading areas in scientific production on HTLV. In HTLV-2, the interest of research in European countries was greater than in Asian countries such as Japan. Europe, which has more IDUs, had more cases for HTLV infection, which consequently arouses interest in HTLV-2 research. Moreover, USA and Europe have a long tradition of agencies and institutions implementing research and health programs and lead in scientific production. North America, Japan and Europe are at the vanguard of scientific excellence and development, and should increase their collaboration with scientific publications in developing countries, especially publications in the field of HTLV from Latin America and the Caribbean.

The progressive growth in collaboration over the last few decades is one of the defining features of the evolution of science[@B43] ^,^ [@B44]. By applying SNA to coauthorship in scientific publications, we identified the existing research groups in the field and the principal investigators active in them. Within the networks, it is possible to distinguish a few nodes that stand out from the rest. These nodes, identified through centrality measures, represent a limited number of influential authors who act as intermediates, favoring cohesion between different areas of the network and facilitating a rapid connection (i.e. a minimal number of steps) between the researchers and groups that participate in the broader network. A few nodes play also an important role as \"bridges\" that connect different foci in the network. If these authors disappear, the overall connectivity of the network would diminish, and its effectiveness would be undermined[@B45]. Although there is no consensus on the exact significance of centrality measures, some studies have related these measures to the greater quantity or quality of research produced[@B46]; or they have been used as a predictor of preferential attachment by newcomers to the research community[@B47].

We used the PubMed database because it is easily accessible and widely used; it uses a controlled vocabulary for indexing and recovering documents[@B32] ^,^ [@B33] ^,^ [@B35], and the index journal in Medline has a certain criteria for quality[@B33]. However, the method we used may have several limitations, which have been explained in other publications[@B04]. For example, the database mainly includes journals published in English, and journals in other languages are less likely to be found in PubMed. However, this database has more non-English journals than the Web of Science database[@B48]. Another limitation is that in PubMed, only the first author\'s address appear in the journal articles, so it is not possible to estimate the quantity of articles from multinational collaborations. This may cause some problems when estimating research productivity from developing countries that work in collaboration with scientists from a developed country. Even though the bibliometric methodology used may present some limitations and the results could, in some way, be biased[@B49] ^,^ [@B50], we believe that this study represents a useful tool for scientists and public health policy makers to plan and organize research in the field of HTLV.

CONCLUSIONS
===========

Authors affiliated with institutions in Japan and USA led scientific production in HTLV research. Efforts should be made to help low-income countries with the highest prevalence of HTLV to promote scientific research networks (collaborative platforms) with Japan, North American and/or European countries in order to increase research based on virology, epidemiology, and/or clinical implications of HTLV infection. HTLV infection is a life-long infection and is currently incurable and untreatable. For this reason, HTLV infection, as a neglected disease, would provide more focus on this condition, perhaps increasing the number of researchers in this field and promoting research collaboration, which could lead to the development of better treatment options for patients.
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